Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

BREATH-SENSE Miniaturized plasma emission spectroscopy-based breath analysis for unobtrusive at-home monitoring and prediction of COPD exacerbations

Coordinator
Academisch Ziekenhuis Leiden, Netherlands
Runs
1 November 2023 to 30 April 2027
Status
Running
EU funding
€3.5m
Total cost
€3.5m
Partners
5 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101115028

What the project is doing

In the project's own words, from its summary on CORDIS.

Patients suffering from Chronic Obstructive Pulmonary disease (COPD) suffer from persistent airway obstruction causing shortness of breath and extreme fatigue. Patients are repeatedly hospitalized due to acute flare-ups known as exacerbations, which are largely responsible for the morbidity and mortality associated with COPD. Exacerbations are diagnosed based on symptoms only and diagnosis is often too late. There is an urgent need for a reliable technology for unobtrusive and continuous at-home monitoring of COPD patients to enable timely exacerbation prediction and treatment.

The Breath-Sense consortium aims to develop the first-ever hand-held breathalyzer for non-invasive detection of breath biomarkers. RespiQ has developed a breakthrough plasma emission spectroscopy-based breath analysis technology, and will collaborate with sensor development expert SINTEF, user-experience and co-creation expert NeLL and clinical COPD specialist KCL. The consortium will combine innovative technological advancements with human-centric user-experience research to develop and validate a transformative clinical workflow for at-home monitoring of COPD patients.

With this digital biomarker-based monitoring solution, patients and clinicians will benefit from reliable and timely prediction of exacerbations, leading to early treatment intervention and preventing up to 95% hospitalizations. The Breath-Sense workflow will deliver a paradigm shift in COPD management, from symptom-based delayed diagnosis towards preventative at-home monitoring prior to symptom worsening. Ultimately, the breathalyzer technology is a platform technology that can be applicable for a wide range of respiratory and gastrointestinal diseases that could also be monitored better continuously at home such as asthma, lung cancer, and IBS, since novel biomarkers can be incorporated for different disease indications.

As such, the Breath-Sense technology has the potential to improve the health of millions of people.

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis LeidenLeidenNetherlandsCoordinator
Respiro BVAmsterdamNetherlandsParticipant
Sintef ASTrondheimNorwayParticipant
Uroboptics - Technical Consulting & Research, LdaIdanha-A-NovaPortugalParticipant
King's College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI